港股異動 | 康方生物-B(9926.HK)漲超8% 旗下PD-1獲FDA突破性療法認定
格隆匯3月30日丨 康方生物-B(9926.HK)漲超8%,報51.2港元,總市值418億港元。康方生物今日發佈公吿,公司與中國生物製藥(01177.HK)共同開發的PD-1單抗藥物派安普利單抗(安尼可)(研發代號:AK105)三線治療轉移性鼻咽癌,獲得美國食品藥品監督管理局(“FDA”)授予突破性療法認定。這是繼FDA授予派安普利單抗三線治療轉移性鼻咽癌快速審批通道和孤兒藥資格後,派安普利在美國取得的又一重要進展。這也是公司第二個腫瘤藥物獲得突破性療法認定。中國生物製藥(01177.HK)則漲約2%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.